Oxford Biomedica Plc (OXB)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance

Current Price

as of Jan 20, 2025

$4.95

P/E Ratio

N/A

Market Cap

$525.43M

Jan 30, 2024Mar 8, 2024Apr 10, 2024May 20, 2024Jun 21, 2024Jul 24, 2024Aug 27, 2024Oct 2, 2024Nov 4, 2024Dec 5, 2024Jan 20, 2025$0.00$10.00
  • PVT
Description

Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The firm also provides bioprocessing and process development services to third parties. It operates through the following segments: Platform and Product. The Platform segment consists of the revenue generating bioprocessing and process development activities undertaken for third parties. The Product segment includes clinical and preclinical development of in vivo and ex vivo gene and cell therapy products which are owned by the group. The company was founded by Alan J. Kingsman and Susan M. Kingsman in 1995 and is headquartered in Oxford, the United Kingdom.

Metrics

Overview

  • HQOxford, OX
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerOXB
  • Price$4.945961-0.26%

Trading Information

  • Market cap$525.43M
  • Float73.60%
  • Average Daily Volume (1m)87,422
  • Average Daily Volume (3m)127,606
  • EPS-$1.63

Company

  • Revenue$89.54M
  • Rev growth (1yr)-36.04%
  • Net incomeN/A
  • Gross marginN/A
  • EBITDA margin-67.17%
  • EBITDAN/A
  • EVN/A
  • EV/Revenue2.50
  • P/EN/A
  • P/S4.38
  • P/B6.44
Documents